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Fatigue, which complicates the course of chronic liver disease [1]
and of primary biliary cirrhosis (PBC) in particular [2], has been
the focus of attention of hepatologists for almost three decades.
Reports on the incidence of signiﬁcant fatigue among PBC
patients in the Western hemisphere vary between 30% and 80%
and fatigue is now a well-recognized symptom in PBC patients
signiﬁcantly contributing to a reduced quality of life. Less is
known regarding the interrelationship between fatigue and the
prognosis of PBC. A previous, initial observation in a well-deﬁned
cohort of PBC patients in North-Eastern England followed for
4 years suggested that the degree of fatigue in PBC patients is
associated with increased mortality and is not affected by urso-
deoxycholic acid (UDCA) therapy [3]. In an earlier report,
increased mortality risk among PBC patients in the UK was also
linked to ‘‘non-liver causes”, such as cardiac disease, and not only
to end-stage liver disease and its sequelae [4]. In this context it is
important to raise the question whether chronic inﬂammatory
liver disease leads to extrahepatic and systemic effects, such as
fatigue, which have an impact on the prognosis of PBC. The path-
ogenesis of fatigue in PBC is only partially understood and is most
likely unrelated to the histological disease stage, degree of hepa-
tic dysfunction, or autoimmune markers. However, fatigue may
possibly be related to cholestasis as well as to reduced clearance
of poorly deﬁned humoral factors and increased accumulation of
inﬂammatory cytokines such as IL-6. Either as a consequence or
independently from these factors, patients may develop auto-
nomic nerve dysfunction, hypotension, muscle dysfunction, and
a disturbed sleep pattern [2].
In this issue of the journal, Jones and co-workers (see page
911) extend their original 4 year observation reported in 2006
[3] to a 9 year follow-up of a well-deﬁned cohort of PBC patients
residing in a United Kingdom community. The control population
for this study was recruited prospectively through primary care
physicians and was well matched. This longer follow-up enabled
conﬁrmation of some of the original observations including theJournal of Hepatology 20
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scores (FIS), the favorable impact of UDCA on survival in respond-
ers to treatment, and the lack of signiﬁcant improvement in fati-
gue following UDCA treatment. Furthermore, the low incidence of
liver-related death observed in fatigued patients who still had a
higher risk for death or for liver transplantation leads the inves-
tigator to suggest that fatigue by itself may be contributing a risk
factor for a poor prognosis in PBC. Indeed, using Cox regression
analysis in a multivariate survival model, the severity of fatigue
was shown to be independently associated with death or liver
transplantation irrespective of deteriorated liver function tests.
In other words, patients with a lower FIS had a better prognosis.
In the ‘‘good old days” of liver transplantation, severe fatigue was
considered by some transplant teams as an important indication
for liver transplantation. To date, in the new MELD era, the pres-
ence of fatigue, as severe as it may be, is no longer taken into con-
sideration in the prioritization of PBC candidates for liver
transplantation. Before further consideration is given to changing
the rules again, one should remember that fatigue cannot be
directly correlated with the severity of liver disease and may
remain stable for years before it gets worse. Further attention
should be devoted to studies on the pathogenesis of fatigue and
the interrelation between fatigue, chronic inﬂammation, and car-
diac disease. Finally, this report contains a wealth of additional
information not discussed in this Focus chapter, which will be
of interest to clinicians who follow patients with PBC.References
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